Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Desvenlafaxine is a widely prescribed antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitors (SNRIs). Its chemical identity is defined by the molecular formula C17H27NO3 and the CAS registry number 317156-88-4. As the primary active metabolite of venlafaxine, desvenlafaxine was developed to offer enhanced pharmacokinetic consistency by bypassing extensive first-pass metabolism in the liver, thereby reducing inter-patient variability in drug response. This structural modification allows for a more predictable therapeutic effect across diverse populations.
The primary clinical application of desvenlafaxine is the treatment of major depressive disorder (MDD) in adults. It functions by inhibiting the reuptake of both serotonin and norepinephrine into presynaptic neurons, effectively increasing the concentration of these neurotransmitters in the synaptic cleft. This mechanism helps restore the chemical balance in the brain associated with mood regulation, alleviating symptoms such as persistent sadness, loss of interest, fatigue, and sleep disturbances. Unlike some other antidepressants, desvenlafaxine demonstrates a balanced inhibition profile, targeting both monoamines without significant affinity for histamine or muscarinic receptors, which often contributes to a lower incidence of certain side effects like sedation or dry mouth compared to older tricyclic agents.
Clinicians typically prescribe immediate-release tablets for once-daily administration, though extended-release formulations are also common to maintain steady plasma levels. While generally well-tolerated, patients may experience common adverse effects including nausea, dizziness, insomnia, and sweating. Serious risks involve potential increases in blood pressure and the risk of serotonin syndrome when combined with other serotonergic drugs. Due to its efficacy and favorable metabolic profile, desvenlafaxine remains a cornerstone therapy in modern psychiatry for managing depression, offering a reliable option for patients who require robust symptom relief with a manageable safety profile.